spacer
spacer

PDBsum entry 3vqh

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Transferase/transferase inhibitor PDB id
3vqh

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
347 a.a.
20 a.a.
Ligands
IQB
MPD
Waters ×178
PDB id:
3vqh
Name: Transferase/transferase inhibitor
Title: Bromine sad partially resolves multiple binding modes for pka inhibitor h-89
Structure: Camp-dependent protein kinase catalytic subunit alpha. Chain: a. Synonym: pka c-alpha. Engineered: yes. Camp-dependent protein kinase inhibitor alpha. Chain: b. Fragment: unp resodues 6-25. Synonym: pki-alpha, camp-dependent protein kinase inhibitor, muscle/brain isoform.
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: pkaca, prkaca. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Other_details: the peptide fragment of pki was synthesized by gl biochem (shanghai) ltd.
Resolution:
1.95Å     R-factor:   0.192     R-free:   0.234
Authors: A.Pflug,K.A.Johnson,R.A.Engh
Key ref: A.Pflug et al. (2012). Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89. Acta Crystallogr Sect F Struct Biol Cryst Commun, 68, 873-877. PubMed id: 22869112
Date:
23-Mar-12     Release date:   15-Aug-12    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P17612  (KAPCA_HUMAN) -  cAMP-dependent protein kinase catalytic subunit alpha from Homo sapiens
Seq:
Struc:
351 a.a.
347 a.a.*
Protein chain
Pfam   ArchSchema ?
P61925  (IPKA_HUMAN) -  cAMP-dependent protein kinase inhibitor alpha from Homo sapiens
Seq:
Struc:
76 a.a.
20 a.a.
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: Chain A: E.C.2.7.11.11  - cAMP-dependent protein kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
2. L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
L-seryl-[protein]
+ ATP
= O-phospho-L-seryl-[protein]
+ ADP
+ H(+)
L-threonyl-[protein]
+ ATP
= O-phospho-L-threonyl-[protein]
+ ADP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
Acta Crystallogr Sect F Struct Biol Cryst Commun 68:873-877 (2012)
PubMed id: 22869112  
 
 
Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89.
A.Pflug, K.A.Johnson, R.A.Engh.
 
  ABSTRACT  
 
With its ability to show the interactions between drug-target proteins and small-molecule ligands, X-ray crystallography is an essential tool in drug-discovery programmes. However, its usefulness can be limited by crystallization artifacts or by the data resolution, and in particular when assumptions of unimodal binding (and isotropic motion) do not apply. Discrepancies between the modelled crystal structure and the physiological range of structures generally prevent quantitative estimation of binding energies. Improved crystal structure resolution will often not aid energy estimation because the conditions which provide the highest rigidity and resolution are not likely to reflect physiological conditions. Instead, strategies must be employed to measure and model flexibility and multiple binding modes to supplement crystallographic information. One useful tool is the use of anomalous dispersion for small molecules that contain suitable atoms. Here, an analysis of the binding of the kinase inhibitor H-89 to protein kinase A (PKA) is presented. H-89 contains a bromobenzene moiety that apparently binds with multiple conformations in the kinase ATP pocket. Using anomalous dispersion methods, it was possible to resolve these conformations into two distinct binding geometries.
 

 

spacer

spacer